CUPiD: A cfDNA methylation-based tissue-of-origin classifier for Cancers of Unknown Primary

Author:

Rothwell Dominic1,Conway Alicia-Marie1ORCID,Pearce Simon1ORCID,Clipson Alexandra2ORCID,Hill Steven3ORCID,Chemi Francesca4,Slane-Tan Daniel1,Ferdous Saba5,Hoss A S Md Mukarram1,Kamieniecka Katarzyna6,White Daniel1,Mitchell Claire7,Kerr Alastair1ORCID,Krebs Matthew8,Brady Ged1,Dive Caroline1,Cook Natalie9ORCID

Affiliation:

1. Cancer Research UK Manchester Institute

2. CRUK Manchester Institute

3. Cancer Research UK Manchester Institute, The University of Manchester

4. Human Technopole

5. University College London

6. University of Bradford

7. The Christie NHS Foundation Trust

8. Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre

9. Christie Hospital NHS Foundation Trust and University of Manchester

Abstract

Abstract Cancers of Unknown Primary (CUP) remains a diagnostic and therapeutic challenge due to biological heterogeneity and poor responses to standard chemotherapy. Predicting tissue-of-origin (TOO) molecularly could help refine this diagnosis, with tissue acquisition barriers mitigated via liquid biopsies. However, TOO liquid biopsies have yet to be explored in CUP cohorts. Using publicly available DNA methylation data, we developed a machine learning classifier termed CUPiD with accurate TOO predictions across 29 tumour classes. We tested CUPiD on 143 cfDNA samples from patients with 13 cancer types alongside 27 non-cancer controls, with overall sensitivity of 84.6% and TOO accuracy of 96.8%. In an additional cohort of 41 patients with CUP CUPiD predictions were made in 32/41 (78.0%) cases, with 88.5% of the predictions clinically consistent with a subsequent or suspected primary tumour diagnosis, when available (23/26 patients). Combining CUPiD with cfDNA mutation data demonstrated potential diagnosis re-classification and/or treatment change in this hard-to-treat cancer group.

Publisher

Research Square Platform LLC

Reference74 articles.

1. A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary;Posner A;J Pathol,2022

2. A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience;Pauli C;Oncologist,2021

3. Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Krämer A;Ann Oncol,2022

4. Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary;Moon I;Nat Med,2023

5. Treatment for Patients With Unknown Primary Cancer and Favorable Prognostic Factors;Hainsworth JD;Semin Oncol,2009

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3